

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

PRELIMINARY RESULTS FOR THE YEAR OF 2025

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively as the “**Group**”) pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The major financial data for the year of 2025 set forth in this announcement are only preliminary accounting data and have not been audited by an accounting firm. The specific data shall be based on the Company’s annual report for the year of 2025. Investors are advised to pay attention to the investment risks involved.

I. MAJOR FINANCIAL DATA AND INDICATORS FOR THE YEAR OF 2025

Unit: RMB

Items	Current Reporting Period	Corresponding Period of Last Year	Rate of Increase/ Decrease (%)
Total operating revenue	1,043,768,680.27	805,857,022.19	29.52
Operating profit	301,753,694.59	130,714,693.96	130.85
Gross profit	301,220,328.25	131,599,169.07	128.89
Net profit attributable to owners of the parent company	272,124,670.05	124,988,009.59	117.72
Net profit attributable to owners of the parent company after deducting non-recurring profit or loss	255,107,825.37	94,536,002.40	169.85
Basic earnings per share (RMB)	0.71	0.33	115.15
Weighted average return on net assets	9.28	4.37	Increase by 4.91 percentage points

	End of the Current Reporting Period	Beginning of the Current Reporting Period	Rate of Increase/ Decrease (%)
Total assets	3,659,165,538.06	3,465,734,982.98	5.58
Owner's equity attributable to the parent company	2,985,050,158.61	2,819,902,283.28	5.86
Share capital	383,568,500.00	383,568,500.00	—
Net assets per share attributable to owners of the parent company (RMB)	7.78	7.35	5.86

- Notes:
1. The data for the beginning of the current reporting period is the same as the data for the end of last year as required to be disclosed by law.
 2. For those companies preparing consolidated financial statements, the data above shall be extracted from the consolidated statements. Where financial data for the same period last year has been restated, the restated figures shall be disclosed concurrently.

II. EXPLANATION OF THE OPERATING RESULTS AND FINANCIAL POSITION

(I) Operating Conditions, Financial Position and Major Factors Affecting Operating Results During the Reporting Period

During the reporting period, the Company's growth potential was constantly unlocked following the implementation of the centralized product procurement policy, and the Company steadily advanced its international operations, forming a synergy between domestic and international operations to enable robust revenue growth. Concurrently, the Company continuously optimized operational management and resource allocation, further enhancing operational efficiency and profitability, and collectively facilitating a solid performance growth.

The total operating revenue of the Company amounted to RMB1,043,768,680.27, representing an increase of 29.52% over the same period of last year; the net profit attributable to owners of the parent company amounted to RMB272,124,670.05, representing an increase of 117.72% over the same period of last year.

At the end of the reporting period, total assets of the Company amounted to RMB3,659,165,538.06, representing an increase of 5.58% over the beginning of the period; the owners' equity attributable to the parent company amounted to RMB2,985,050,158.61, representing an increase of 5.86% over the beginning of the period; and the net assets per share attributable to owners of the parent company amounted to RMB7.78, representing an increase of 5.86% over the beginning of the period.

(II) Main Reasons for the Increase/Decrease of 30% or more of the Relevant Items in the above Table

During the reporting period, the Company's operating profit, the gross profit, the net profit attributable to owners of the parent company, the net profit attributable to owners of the parent company after deducting non-recurring profit or loss, and the basic earnings per share all increased significantly compared to the same period last year. The primary reasons are as follows:

1. With the normalization of national centralized procurement for orthopedic consumables, the Company leveraged its comprehensive channel coverage network and extensive product portfolio to achieve steady growth in product sales. Domestic business scale and market share continued to expand, driving a steady increase in profitability.
2. The Company continued to advance its internationalization strategy. Leveraging product technologies and quality standards that meet internationally advanced levels, it achieved sustained business expansion and breakthroughs in the international market. Overseas revenue steadily increased, providing significant support for the Company's overall performance growth.

Meanwhile, the Company focused on refined operational management to optimize efficiency, and further amplified economies of scale through scaled production, facilitating a significant improvement in overall operational efficiency and profitability.

III. RISK WARNING

There are no significant uncertainties affecting the accuracy of the preliminary results. The major financial data for the year of 2025 set forth in this announcement are only preliminary accounting data and have not been audited by an accounting firm. The specific and accurate financial data shall be based on those data in the audited 2025 annual report to be formally disclosed by the Company. Investors are advised to pay attention to the investment risks involved.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Chairman
Shi Wenling

Beijing, the PRC, 27 February 2026

As at the date of this announcement, the executive Directors are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director is Mr. Wang Xin; and the independent non-executive Directors are Ms. Xu Hong, Mr. Weng Jie and Mr. Wong Tak Shing.

* For identification purposes only